New medications in the treatment of diabetes are an active area of research and drug development. Although many hypoglycemic therapies have been in use for decades, new evidence continues to emerge highlighting benefits of these medications for other indications. In this article, the authors review the classes of newer hypoglycemic agents and summarize medications currently in phase 2 and 3 clinical trials. The literature to support specific recommendations for perioperative management is scant, however, where it exists, we have included it. In other instances, the authors have noted a reasonable approach based on pharmacokinetics and principles of perioperative medication management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.anclin.2023.08.004 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!